Visit NavNeuro at:

Episode 20 | The Interplay Between Cerebrovascular Disease and Alzheimer's Disease - With Dr. Adam Brickman


Adam Brickman, Ph.D., returns to discuss the involvement of white matter disease in Alzheimer’s disease progression and clinical presentation. Dr. Brickman discusses his research on the presence of biomarkers of cerebrovascular disease (e.g., white matter hyperintensities), which are present in aging and Alzheimer’s disease. Although cerebrovascular disease is traditionally associated with its own unique cognitive profile, Dr. Brickman discusses evidence suggesting that the cognitive deficits and underlying etiologies often commingle and complicate our case conceptualization. Additionally, he proposes the integral role that cerebrovascular disease may play in predicting (and possibly initiating) disease progression and cognitive decline in Alzheimer’s disease.

apa-logo_white_screenThe International Neuropsychological Society is approved by the American Psychological Association to sponsor continuing education for psychologists. The International Neuropsychological Society maintains responsibility for this program and its content.

Adam Brickman
Instructor Credentials

Adam Brickman, Ph.D., is the Herbert Irving Associate Professor of Neuropsychology in the Department of Neurology at Columbia University, the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, the Gertrude H. Sergievsky Center. Dr. Brickman has published over 200 peer-reviewed manuscripts and received the 2019 Arthur Benton Mid-Career Research Award for his scientific contributions in the field of cognitive aging and Alzheimer’s disease. Specifically, he is interested in white matter abnormalities and the intersection between vascular disease and Alzheimer’s disease. He is also interested in using advanced neuroimaging techniques, traditional neuropsychological tests, and functional assessment to understand how cognitive reserve and cerebrovascular risk factors interact with the aging brain and cognitive abilities.

Dr. Brickman has served as a member of the Aging Systems and Geriatrics Study Section for the National Institutes of Health and as a member of the editorial board of the Journal of the International Neuropsychological Society (JINS) and Neuropsychology Review. He has held several leadership roles, including co-chairing and chairing the Division 40 (Clinical Neuropsychogy) program committee in 2010 and 2011, serving on the Division 40 Scientific Advisory Committee since 2007, and serving as the only neuropsychologist on the APA Committee on Aging.

Topics Covered
  • Mechanism of risk factors for cerebrovascular disease (10:20)
  • Reduced cerebral autoregulation of blood pressure increases risk for cerebrovascular disease and cognitive decline (12:50)
  • Cognitive decline and cerebrovascular disease (16:45)
  • Conceptualizing, assessing, and treating mixed dementia (19:20)
  • Patterns of white matter disease and cognitive profiles (24:00)
  • Clinical radiological readings and white matter hyperintensities in aging (28:42)
  • 2016 Annals of Neurology paper discussion (30:40)
  • Cerebral amyloid angiopathy in Alzheimer’s disease (35:05)
  • Cerebrovascular disease as a possible initiator of Alzheimer’s disease (36:55)
  • Moderators of the impact of cerebrovascular disease on cognition (40:20)
  • White matter changes in age-related cognitive decline (47:20)
  • Interventions to reduce risk of cerebrovascular disease (49:52)
Educational Objectives
  • List the various health and lifestyle factors that may impact risk of cerebrovascular disease
  • Discuss the impact of cerebrovascular disease on cognitive decline
  • Explain the relationship between cerebrovascular disease and Alzheimer's disease
Target Audience
  • Introductory
  • Date Available: 2019-05-15
  • You may obtain CE for this podcast at any time.
Offered for CE
  • Yes
  • Members $20
  • Non-Members $25
Refund Policy
  • This podcast is not eligible for refunds
CE Credits
  • 1.0 Credit(s)
  • N/A
  • N/A
  • Brickman, A. M. (2013). Contemplating Alzheimer’s disease and the contribution of white matter hyperintensities. Current neurology and neuroscience reports, 13(12), 415.
  • Brickman, A. M., Honig, L. S., Scarmeas, N., Tatarina, O., Sanders, L., Albert, M. S., . . . Stern, Y. (2008). Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Archives of neurology, 65(9), 1202-1208.
  • Brickman, A. M., Muraskin, J., & Zimmerman, M. E. (2009). Structural neuroimaging in Alzheimer’s disease: do white matter hyperintensities matter? Dialogues in clinical neuroscience, 11(2), 181.
  • Brickman, A. M., Reitz, C., Luchsinger, J. A., Manly, J. J., Schupf, N., Muraskin, J., . . . Mayeux, R. (2010). Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Archives of neurology, 67(5), 564-569.
  • Brickman, A. M., Siedlecki, K. L., Muraskin, J., Manly, J. J., Luchsinger, J. A., Yeung, L.-K., . . . Stern, Y. (2011). White matter hyperintensities and cognition: testing the reserve hypothesis. Neurobiology of aging, 32(9), 1588-1598.
  • Brickman, A. M., Zahodne, L. B., Guzman, V. A., Narkhede, A., Meier, I. B., Griffith, E. Y., . . . Stern, Y. (2015). Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer’s disease incidence. Neurobiology of aging, 36(1), 27-32.
  • Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., . . . Brickman, A. M. (2013). White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA neurology, 70(4), 455-461.
  • Van Beek, A. H., Claassen, J. A., Rikkert, M. G. O., & Jansen, R. W. (2008). Cerebral autoregulation: an overview of current concepts and methodology with special focus on the elderly. Journal of Cerebral Blood Flow & Metabolism, 28(6), 1071-1085.